Please login to the form below

Not currently logged in
Email:
Password:

Novartis buys cancer specialist Endocyte for $2.1bn

Acquisition includes 'universal' CAR-T platform

Novartis Basel

Novartis has agreed another bolt-on deal to boost its pipeline, buying nuclear medicine firm Endocyte for $2.1bn as it raised its sales forecasts for the year on a strong third quarter.

The $24-per-share offer – around $8.50 above Endocyte’s closing share price yesterday – has the backing of the biotech’s board, but still needs the approval of its shareholders.

Novartis wants to merge the company with a newly-formed subsidiary that will focus on radiopharmaceutical drugs for cancer, with Endocyte’s portfolio blended with in-house assets such as Lutathera (177Lu- oxodotreotide) for gastroenteropancreatic neuroendocrine (GEP-NET) tumours, acquired along with French company Advanced Accelerator Applications for $3.9bn a year ago.

Heading up Endocyte’s pipeline is 177Lu-PSMA-617, a potential first-in-class drug for the treatment of metastatic castration-resistant prostate cancer (CRPC). The drug targets prostate-specific membrane antigen (PSMA), which is expressed on prostate cancer cells, and delivers a cell-killing radioisotope directly to the tumour. It is currently in a phase 3 registration trial – called VISION – that is due to report results in 2020.

Novartis said radiopharma is a “key growth driver” for its business  and that Endocyte’s offer “significant sales potential” from 177Lu-PSMA-617, particularly if its use can be extended into earlier-stage prostate cancer, as well as early-stage development programmes.

The latest deal comes shortly after Novartis agreed a $8.7bn deal to acquire AveXis, a US specialist in spinal muscular atrophy (SMA).

It’s worth pointing out that buying Endocyte also gives Novartis an additional platform in CAR-T cancer immunotherapy to complement its current assets, including already-marketed therapy Kymriah (tisagenlecleucel) for CD19-positive blood cancers. Endocyte has developed an approach that could be used to generate a single, universal CAR-T therapy for multiple cancer types which is currently in preclinical development.

Cosentyx

Cosentyx saw its sales rise 37%

News of the latest bolt-on deal came as Novartis revealed a 6% rise in third-quarter sales to $12.8bn in constant currencies on the back of gains for new psoriasis drug Cosentyx (secukinumab) and Entresto (sacubitril/valsartan) for heart failure – up 37% to $750m and 113% to $271m, respectively – as well as Sandoz’ biosimilar drugs.

Lutathera brought in $56m as it continues to roll out in the US following FDA approval in January, which Novartis said was a good performance, but while CAR-T Kymriah saw sales last triple year-on-year they remained low at $20m, up from $16m in the second quarter. The company has been working to resolve product consistency issues that have disrupted supplies.

18th October 2018

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Syneos Health®

Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and...

Latest intelligence

The doctor will text you now: Why healthcare providers cannot underestimate the importance of communicating change
Healthcare communication needs to switch from ‘transmit’ to ‘receive’, listening to what patients need and embracing the plethora of communication tools wholeheartedly....
How to innovate and influence people in times of misinformation
The pandemic has shown that public trust in promising new medical technologies is far from a given. Senior Writer Tom Vandyck at StoneArch, a member of Fishawack delves into the...
Could femtech be the answer to the gender health gap?
Here, we discuss the phenomenon of femtech, an industry that puts women’s experiences of lifestyle and health front and centre. We highlight some of the major players in the industry,...